Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1814 clinical trials
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.

measurable disease
ejection fraction
solid neoplasm
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Safety Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

There are 6 Groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 subjects were included in each of the S2 ~ S6 groups (of which 8 received study drugs …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

If SNG001 proves to be beneficial it would be a major breakthrough for the treatment of COVID-19.

covid-19
acute respiratory syndrome (sars)
chronic obstructive pulmonary disease
fever
cough
  • 0 views
  • 01 Feb, 2023
  • 9 locations
NoIAmNot Trial

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 21 Feb, 2023
enrolling Trial

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 22 Feb, 2023
COPD-ICU Multicentre Prospective Observational Register (COPD-ICU)

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 21 Feb, 2023
second sync

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 21 Feb, 2023
scrumsecond sync

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 22 Feb, 2023
  • 1 location
scrumsecond sync

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 25 Feb, 2023
scrumsecond sync

Based on the Stage 1 analysis performed in November 2014, Arm 1 was chosen for expansion in Stage 2. Stage 2 dose will be 1-5x10xE8 transduced CART-19 cells. The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% …

  • 0 views
  • 25 Feb, 2023